Table 1 Characteristics of patients in two groups

Baseline Characteristics

 Female (n (%))

4 (22%)

11 (30.6%)

0.332

172 (50.7%)

 Age(year)

64 ± 2

63 ± 2

0.563

63 ± 1

 HR (beats/min)

63 ± 2

68 ± 2

0.144

72 ± 1

 BMI(kg/m²)

24.1 ± 0.7

24.6 ± 0.5

0.641

24.1 ± 0.2

Medical history, n (%)

 Hypertension

11 (61%)

26 (83%)

0.149

198 (58.4%)

 CAD

9 (45%)

11 (31%)

0.314

77 (22.7%)

 CKD(stage ≥ 3)or ESRD

1 (6%)

1 (3%)

1.000

24 (7.1%)

 COPD

1 (6%)

1 (3%)

1.000

8 (2.4%)

 Diabetes

3 (17%)

8 (25.8%)

0.701

70 (20.6%)

Medication, n (%)

 β-Blockers

5 (28%)

17 (55%)

0.066

——

 ACEI

5 (28%)

8 (26%)

0.880

——

 ARBs

3(17%)

11 (35.5%)

0.160

——

 Calcium blocker

5 (28%)

14 (45%)

0.368

——

 Diuretics

2 (11%)

3 (10%)

0.873

——

 Statins

18 (100%)

30 (97%)

1.000

——

 Nitrates

5 (28%)

8 (26%)

1.000

——

 Antiplatelet drugs

20 (100%)

35 (100%)

1.000

——

 Angiographic findings

——

Numbers of vessels with significant stenosis > 50%

——

 1

3

6

1.000

——

 2

2

2

0.974

——

 3

2

2

0.623

——

Vessels with stenosis > 50%

——

 LM

1

2

1.000

——

 LAD

5

6

0.744

——

 LCX

5

2

1.000

——

 RCA

1

3

1.000

——

Echocardiographic Variables

 Mitral E (cm/s)

66 ± 2

71 ± 2

0.143

79 ± 1

 Mitral A (cm/s)

75 ± 4

88 ± 4

0.045

86 ± 1

 E/A ratio

0.8 (0.7—1.0)

0.8 (0.7—0.9)

0.383

0.9 (0.8—1.1)

 Septal e′ velocity (cm/s)

6.8 ± 0.5

6.3 ± 0.3

0.363

6.4 ± 0.1

 Lateral e′ velocity (cm/s)

10 (7.8—12.0)

8.0 (6.0—10.4)

0.144

9(6—11)

 E/e’_mean ratio

8.0 (6.8—10.6)

10 (8.2—11.2)

0.078

10 (8—15)

 TR peak velocity (m/s)

2.3 (2.1—2.5)

2.2 (2.1—2.6)

0.949

2.5 (2.3—2.8)

 LVEF (%)

66 ± 2

64 ± 1

0.733

64 ± 1

 LAVimax (ml/m2)

14.6 ± 1.7

16.5 ± 1.2

0.388

32.5 ± 0.7

 LAEF (%)

55 ± 2

55 ± 2

0.851

54 ± 1

 LASr(%)

32.9 ± 1.5

23.2 ± 1.2

 < 0.001

27.2 ± 0.5

 E/LASr ratio

2.0 (1.8—2.2)

3.0 (2.6—4.0)

 < 0.001

2.7 (2.1—3.8)